Phase 1 clinical trials evaluate the safety and dosage of proposed new treatments. Further research is needed to test the oncolytic virus therapy’s effectiveness and side effects. Work also continues ...

Glioblastoma, the most aggressive and deadly type of brain cancer, is known to have a very poor prognosis — but a new study suggests that a pain-relieving drug could extend survival. Researchers at ...

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company ...

A modified herpes virus boosted immune T cell infiltration in glioblastoma tumors and was associated with improved survival.

Glioblastoma is the most aggressive and deadliest form of brain cancer. Most patients survive only about a year after diagnosis, and just 5% make it to five years. Dr. Minesh P. Mehta is leading the ...

Researchers from the University of Texas Health Science Center at San Antonio have developed a drug that more than doubled median survival time and progression-free time for patients with glioblastoma ...

The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...

For years, cancer researchers have noticed that more men than women get a lethal form of brain cancer called glioblastoma. They've also found that these tumors are often more aggressive in men. But ...